ChemoTech has signed a distributor agreement in Pakistan

Report this content

Today, Monday June 11 2018, ChemoTech signed a distributor agreement with Med Lab Services in Pakistan. The agreement also guarantees an order of at least one IQWave™.

This is a translation of the Swedish press release published on Monday 11th of June 2018.

After a year of several contacts from interested distributors from Pakistan, ChemoTech is pleased to announce that we have signed a distributor agreement with Med Lab Services ('MLS'). MLS has, with its 39 employees, extensive experience sales of modern and technologically advanced products. After ChemoTech has received its CE-mark, MLS will start to launch IQWave™ in Pakistan.

It feels extremely exciting that ChemoTech has signed an agreement with a market like Pakistan, with more than 200 million inhabitants, which will be ChemoTech's second largest market. We believe that the reason for the big demand of IQWave™ D-EECT is a result of the fact that the first generation of electrochemotherapy is already established in some of the Pakistani hospitals.

The agreement with MLS is conditional with an order of at least one IQWave™ and contains sales projections and minimum targets.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

Scandinavian ChemoTech AB (publ)

ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.